• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Trendingnow

1

Gen Z fled San Francisco for Texas and Florida. Now they’re turning ‘welcomer cities’ into the next big tech towns

2

Melinda French Gates' advice to new IPO millionaires: 'Give half your money away'

3

Trump expects to sign a deal with Iran on Sunday, but Tehran may want to avoid giving him a gift on his birthday

1

Gen Z fled San Francisco for Texas and Florida. Now they’re turning ‘welcomer cities’ into the next big tech towns

2

Melinda French Gates' advice to new IPO millionaires: 'Give half your money away'

3

Trump expects to sign a deal with Iran on Sunday, but Tehran may want to avoid giving him a gift on his birthday
HealthCOVID-19 vaccines

RFK Jr. has accused the FDA of suppressing hydroxychloroquine. Now, the study that suggested its use in COVID is retracted.

Beth Greenfield
By
Beth Greenfield
Beth Greenfield
Senior Reporter, Fortune Well
Down Arrow Button Icon
Beth Greenfield
By
Beth Greenfield
Beth Greenfield
Senior Reporter, Fortune Well
Down Arrow Button Icon
December 18, 2024, 2:08 PM ET
Closeup of a bottle of hydroxychloroquine and scattered pills
The study that set of a wave of excitement over hydroxychloroquine and COVID has been retracted. GEORGE FREY/AFP via Getty Images

A study that prompted hope for a COVID-19 treatment in the early days of the pandemic has now been formally retracted by the scientific journal that published it.

Recommended Video

Hydroxychloroquine, an antimalarial drug also approved for use in some autoimmune diseases, was first introduced to the world as a potential cure through a March 2020 study of 36 patients with COVID in the International Journal of Antimicrobial Agents. Elsevier, which owns the journal, issued its formal retraction on Tuesday.

“Concerns have been raised regarding this article, the substance of which relate to the articles’ adherence to Elsevier’s publishing ethics policies and the appropriate conduct of research involving human participants, as well as concerns raised by three of the authors themselves regarding the article’s methodology and conclusions,” the lengthy retraction statement noted, in part.

It is the most highest-cited paper on COVID-19 to be retracted, and the second-most-cited retracted paper of any kind, according to the journal Nature.

The study’s initial publication set off a frenzy of excitement over the drug’s potential. The U.S. Food and Drug Administration issued an Emergency Use Authorization to allow it to be stockpiled and distributed to certain patients hospitalized with COVID. President Donald Trump announced that he was taking it prophylactically, and prescriptions for the drug increased from 1,143 in February 2020 to 75,569 in March 2020, according to the Centers for Disease Control and Prevention.

Yale School of Public Health professor of epidemiology Harvey Risch said in July 2020 he believed that by not approving the drug for COVID use, “tens of thousands of patients with COVID-19 are dying unnecessarily.”

And Robert F. Kennedy Jr., Trump’s pick to head the Department of Health and Human Services, suggested hydroxychloroquine’s use for COVID was being “censored and politicized” in a July 2020 story on his Children’s Health Defense website. “For the biopharma companies poised to profit from new drugs and Covid-19 vaccines—including the alarming Moderna vaccine co-developed by NIAID—it is not an attractive option to keep older drugs that have outlived their patent terms in the running,” the story noted.

The study’s retraction puts an end to a long line of criticism that started almost immediately after its publication, including over its unusually short peer-review time and small sample size.

Elsevier said that other problems with the data included that six patients with results that would’ve changed the study’s positive conclusions were eliminated from the study after it began—something pointed out at the time by Dutch microbiologist Elisabeth Bik, who posted on X on Tuesday that the study was “finally” retracted. Elsevier also could not establish whether the patients had given fully informed consent to be treated with the antibiotic azithromycin, which was part of the study.

Lead author Didier Raoult, a French virologist who founded and directed the research hospital known as the Institut Hospitalo-Universitaire Méditerranée Infection, or IHU, was a controversial figure; 28 of his co-authored studies have now been retracted, according to Science. He faced a disciplinary hearing over recommending hydroxychloroquine for COVID, and was forced to step down from the IHU. He has also been dismissive of climate change, fear of epidemics, and Darwinian evolution.

Hydroxychloroquine has also been linked to serious side effects, including cardiac arrest, heart rhythm issues, liver failure, and kidney disorders, as noted by a 2020 FDA warning about the drug’s use for COVID treatment outside of a hospital setting.

“A dark page in COVID-19 research finally turned,” noted a statement issued this week by the French Society of Pharmacology and Therapeutics. “This highly controversial study was the cornerstone of a global scandal. The promotion of its results led to the overprescription of hydroxychloroquine to millions of patients, resulting in unnecessary risk-taking for millions of people and potentially thousands of avoidable deaths. It also resulted in a massive waste of resources and the proliferation of hundreds of useless studies, to the detriment of research into truly effective treatments.”

More on COVID:

  • Got COVID? Here are the new 2024 isolation guidelines
  • 54 million COVID cases went unreported in 2022, study says. Here’s how to make your at-home test count
  • The return-to-office wars have diminished workplace well-being—especially for these groups
Subscribe to Well Adjusted, our newsletter full of simple strategies to work smarter and live better, from the Fortune Well team. Sign up for free today.
About the Author
Beth Greenfield
By Beth GreenfieldSenior Reporter, Fortune Well

Beth Greenfield is a New York City-based health and wellness reporter on the Fortune Well team covering life, health, nutrition, fitness, family, and mind.

See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.


Latest in Health

Middle-aged adults taking GLP-1s for obesity can save over $192K on lifetime medical costs, higher if they don’t have college degrees, new study finds
HealthHealth
Middle-aged adults taking GLP-1s for obesity can save over $192K on lifetime medical costs, higher if they don’t have college degrees, new study finds
By Mia OsmonbekovJune 14, 2026
8 hours ago
U.S.’s screwworm fix is still a year away, risking more spread
North AmericaAgriculture
U.S.’s screwworm fix is still a year away, risking more spread
By Ilena Peng and BloombergJune 13, 2026
16 hours ago
Meet the lone star tick: the primary U.S. source of alpha-gal syndrome, which is a life-threatening meat allergy that’s on the rise
HealthHealth
Meet the lone star tick: the primary U.S. source of alpha-gal syndrome, which is a life-threatening meat allergy that’s on the rise
By Matthew Perrone and The Associated PressJune 13, 2026
1 day ago
arms
HealthPsychology
You probably think you’re a really open-minded person, but the real thing raises your death anxiety
By Daryl Van Tongeren and The ConversationJune 12, 2026
2 days ago
AI was supposed to cut health care costs. One of its first jobs was charging you more, PwC report shows
AIHealth Care Service
AI was supposed to cut health care costs. One of its first jobs was charging you more, PwC report shows
By Whizy Kim and Tech BrewJune 12, 2026
2 days ago
Plunge All-in Cold Plunge Review (2026): Expert Tested
HealthDietary Supplements
Plunge All-in Cold Plunge Review (2026): Expert Tested
By Christina SnyderJune 12, 2026
2 days ago

Most Popular

Gen Z fled San Francisco for Texas and Florida. Now they’re turning ‘welcomer cities’ into the next big tech towns
Real Estate
Gen Z fled San Francisco for Texas and Florida. Now they’re turning ‘welcomer cities’ into the next big tech towns
By Sydney LakeJune 13, 2026
1 day ago
Melinda French Gates' advice to new IPO millionaires: 'Give half your money away'
Startups & Venture
Melinda French Gates' advice to new IPO millionaires: 'Give half your money away'
By Emma HinchliffeJune 13, 2026
1 day ago
Trump expects to sign a deal with Iran on Sunday, but Tehran may want to avoid giving him a gift on his birthday
Middle East
Trump expects to sign a deal with Iran on Sunday, but Tehran may want to avoid giving him a gift on his birthday
By Jason MaJune 13, 2026
20 hours ago
'It's not a jailbreak' — Research leading to U.S. export restrictions on top Anthropic models was for defense, cybersecurity CEO says
AI
'It's not a jailbreak' — Research leading to U.S. export restrictions on top Anthropic models was for defense, cybersecurity CEO says
By Jason MaJune 13, 2026
22 hours ago
SpaceX CFO Bret Johnsen quietly engineered its historic IPO and became an overnight billionaire
C-Suite
SpaceX CFO Bret Johnsen quietly engineered its historic IPO and became an overnight billionaire
By Sasha RogelbergJune 13, 2026
1 day ago
Anthropic disables Fable and Mythos AI models after U.S. government bars it from giving foreigners access
AI
Anthropic disables Fable and Mythos AI models after U.S. government bars it from giving foreigners access
By Jeremy KahnJune 13, 2026
1 day ago